Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.82
-1.00 (-6.75%)
Sep 15, 2026, 4:00 PM EDT - Market closed
Contineum Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Contineum Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $23.43. The average 1-year stock price forecast is 69.54% higher than the current stock price, while the lowest is $18 (+30.25%) and the highest is $28 (+102.60%).
Price Target: $23.43 (+69.54%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Contineum Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Maintains $25 → $22 | Buy | Maintains | $25 → $22 | +59.19% | Sep 16, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $26 → $24 | Buy | Reiterates | $26 → $24 | +73.66% | Sep 15, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $20 → $19 | Buy | Maintains | $20 → $19 | +37.48% | Sep 15, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $28 | Buy | Maintains | $28 | +102.60% | Sep 15, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $24 → $23 | Buy | Reiterates | $24 → $23 | +66.43% | Sep 14, 2026 |
Financial Forecast
Revenue This Year
5.00M
Revenue Next Year
n/a
from 5.00M
Decreased by -100.00%
EPS This Year
-1.60
from -2.17
EPS Next Year
-1.84
from -1.60
EPS and Forward PE are based on non-GAAP adjusted numbers.